highmark glp 1 coverage MCT2D The evolving landscape of anti-obesity

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Timing is less important than consistency

Protein structures were prepared using Maestro Schrdinger Suite (Schrdinger Release 2025-3: Maestro

[DOI] [PubMed] [Google Scholar] 13.Yao S., Xing S., Shan X., Dai W., Cao Y., Hu B

Carrying extra weight, particularly around the abdomen, is one of the most significant modifiable risk factors for vein disease

it is about maximizing your results